Request Appointment
530 East 74th StreetNew York, NY 10021
Overview of Dr. Shah
Dr. Gunjan Shah is an oncologist in New York, NY and is affiliated with Memorial Sloan Kettering Cancer Center. She received her medical degree from Lewis Katz School of Medicine at Temple University and has been in practice 9 years. She is one of 506 doctors at Memorial Sloan Kettering Cancer Center who specialize in Oncology. She has more than 100 publications and over 500 citings.
Education & Training
- Tufts Medical CenterFellowship, Hematology and Medical Oncology, 2011 - 2014
- Sidney Kimmel Medical College at Thomas Jefferson University/TJUHResidency, Internal Medicine, 2008 - 2011
- Lewis Katz School of Medicine at Temple UniversityClass of 2008
Certifications & Licensure
- FL State Medical License 2021 - Present
- NY State Medical License 2014 - 2027
- PA State Medical License 2023 - 2026
- CT State Medical License 2023 - 2025
- NJ State Medical License 2018 - 2025
- NC State Medical License 2021 - 2022
- MA State Medical License 2011 - 2016
- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Hematology
- American Board of Internal Medicine Medical Oncology
Clinical Trials
- Nivolumab & Brentuximab Vedotin Consolidation After Autologous SCT in Patients With High-Risk Classical Hodgkin Lymphoma Start of enrollment: 2017 Apr 03
Publications & Presentations
PubMed
- T-ICAHT: Grading and Prognostic Impact of Thrombocytopenia After CAR T-cell Therapy.Kai Rejeski, Jaime Sanz, Teng Fei, Monica S Nair, Hamza Hashmi
Blood. 2025-04-21 - CAR T-cell therapy response varies by extranodal disease site in large B-cell lymphoma.Alejandro Luna, Sean M Devlin, Kai Rejeski, Jessica R Flynn, Magdalena Corona
Blood Cancer Journal. 2025-04-14 - Maintenance therapy with romidepsin after autologous stem-cell transplant for peripheral T-cell lymphoma.Niloufer Khan, Parastoo B Dahi, Farhad Khimani, Andrei Shustov, Mazyar Shadman
Blood Advances. 2025-04-03
Abstracts/Posters
- High Complete Response Rate Observed with Second-Line Chemo-Immunotherapy with Pembrolizumab and GVD (Gemcitabine, Vinorelbine, and Liposomal Doxorubicin) in Relapsed ...Gunjan L. Shah, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
- Impact and Safety of Chimeric Antigen Receptor T Cell Therapy in Vulnerable Older Patients with Relapsed/Refractory Diffuse Large B-Cell LymphomaGunjan L. Shah, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
- Easix and Modified-Easix Are Early Predictors of Severe Cytokine Release Syndrome and Neurotoxicity in Patients Treated with Chimeric Antigen Receptor T CellsGunjan L. Shah, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
- Join now to see all
Lectures
- Homebound Autologous Hematopoietic Cell Transplantation for Plasma Cell Disorders in an Urban Setting Is Safe for Patients and Preferred By Patients and Caregivers2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
- Double-Unit Cord Blood (CB) Transplantation with Haplo-Identical CD34+ Cells (haplo-dCBT) May Speed Neutrophil Recovery Although Successful Bridging Is Contingent on C...2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
- Survival for Relapsed/Refractory Hodgkin Lymphoma Patients with Recurrent or Persistent Disease Following Autologous Hematopoietic Stem Cell Transplantation Treated in...2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
- Join now to see all
Press Mentions
- Early Resource Utilization Associated with CAR-T Infusion for Hematologic MalignanciesDecember 4th, 2018
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: